| Pharmacokinetic Studies of Florfenicol in Koi Carp and Threespot Gourami Trichogaster trichopterus after Oral and Intramuscular Treatment RPE Yanong, EW Curtis, R Simmons, VA Bhattaram, M Gopalakrishnan, ... Journal of Aquatic Animal Health 17 (2), 129-137, 2005 | 110 | 2005 |
| Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation M Gamalo‐Siebers, J Savic, C Basu, X Zhao, M Gopalakrishnan, A Gao, ... Pharmaceutical Statistics 16 (4), 232-249, 2017 | 83 | 2017 |
| Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types X Zhao, J Shen, V Ivaturi, M Gopalakrishnan, Y Feng, BJ Schmidt, ... Annals of Oncology 31 (2), 302-309, 2020 | 57 | 2020 |
| Levonorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system MD Creinin, R Jansen, RM Starr, J Gobburu, M Gopalakrishnan, A Olariu Contraception 94 (4), 353-356, 2016 | 38 | 2016 |
| Pharmacokinetics of DFN-15, a novel oral solution of celecoxib, versus celecoxib 400-mg capsules: a randomized crossover study in fasting healthy volunteers A Pal, S Shenoy, A Gautam, S Munjal, J Niu, M Gopalakrishnan, ... Clinical Drug Investigation 37, 937-946, 2017 | 28 | 2017 |
| The trend of increasing placebo response and decreasing treatment effect in schizophrenia trials continues: an update from the US Food and Drug Administration M Gopalakrishnan, H Zhu, TR Farchione, M Mathis, M Mehta, R Uppoor, ... The Journal of Clinical Psychiatry 81 (2), 14594, 2020 | 27 | 2020 |
| Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: a combined analysis of phase II and phase III trials AK Jones, E Ngaimisi, M Gopalakrishnan, MA Young, CM Laffont Clinical Pharmacokinetics 60, 527-540, 2021 | 26 | 2021 |
| Evaluation of linezolid pharmacokinetics in critically ill obese patients with severe skin and soft tissue infections AL Blackman, P Jarugula, DP Nicolau, SH Chui, M Joshi, EL Heil, ... Antimicrobial agents and chemotherapy 65 (2), 10.1128/aac. 01619-20, 2021 | 24 | 2021 |
| Exposure‐response analysis after subcutaneous administration of RBP‐7000, a once‐a‐month long‐acting Atrigel formulation of risperidone V Ivaturi, M Gopalakrishnan, JVS Gobburu, W Zhang, Y Liu, C Heidbreder, ... British journal of clinical pharmacology 83 (7), 1476-1498, 2017 | 24 | 2017 |
| Population pharmacokinetic–pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats M Gopalakrishnan, S Suarez, AJ Hickey, JVS Gobburu Journal of pharmacokinetics and pharmacodynamics 32, 485-500, 2005 | 24 | 2005 |
| A population pharmacokinetics and pharmacodynamic approach to optimize tazobactam activity in critically ill patients SN Kalaria, M Gopalakrishnan, EL Heil Antimicrobial agents and chemotherapy 64 (3), 10.1128/aac. 02093-19, 2020 | 22 | 2020 |
| Vancomycin pharmacokinetics in obese patients with sepsis or septic shock AM Masich, SN Kalaria, JP Gonzales, EL Heil, AL Tata, KC Claeys, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (3 …, 2020 | 21 | 2020 |
| Racial association and pharmacotherapy in neonatal opioid withdrawal syndrome A Parikh, M Gopalakrishnan, A Azeem, A Booth, D El-Metwally Journal of Perinatology 39 (10), 1370-1376, 2019 | 19 | 2019 |
| A model-based exposure-response (ER) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types X Zhao, V Ivaturi, M Gopalakrishnan, J Shen, Y Feng, P Statkevich, ... CANCER RESEARCH 77, 2017 | 18 | 2017 |
| Development of biomarkers for radiation biodosimetry and medical countermeasures research: Current status, utility, and regulatory pathways MM Satyamitra, AL DiCarlo, BA Hollingsworth, TA Winters, LP Taliaferro Radiation research 197 (5), 514-532, 2022 | 16* | 2022 |
| Association of end point definition and randomized clinical trial duration in clinical trials of schizophrenia medications IR Younis, M Gopalakrishnan, M Mathis, M Mehta, R Uppoor, H Zhu, ... JAMA psychiatry 77 (10), 1064-1071, 2020 | 15 | 2020 |
| Parent‐Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients With BRCA 1/2–Mutated Cancer or … J Niu, C Scheuerell, S Mehrotra, S Karan, S Puhalla, BF Kiesel, J Ji, ... The Journal of Clinical Pharmacology 57 (8), 977-987, 2017 | 15 | 2017 |
| Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized … A Bhatia, S Tawade, M Mastim, EN Kitabi, M Gopalakrishnan, M Shah, ... Acta Diabetologica 55, 461-468, 2018 | 13 | 2018 |
| Lacosamide pharmacokinetics in a critically ill patient receiving continuous venovenous hemofiltration MJ Franquiz, SN Kalaria, MJ Armahizer, M Gopalakrishnan, PJ McCarthy, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38 (2 …, 2018 | 13 | 2018 |
| Analysis approaches to identify pharmacogenetic associations with pharmacodynamics DL Hertz, LB Ramsey, M Gopalakrishnan, JS Leeder, SL Van Driest Clinical Pharmacology & Therapeutics 110 (3), 589-594, 2021 | 12 | 2021 |
